Profile
Sector:
HealthcareCountry:
IrelandIPO:
07 June 1996Website:
http://www.avadel.comNext earnings report:
08 November 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 01 Nov 2024 23:58:02 GMTDividend
Analysts recommendations
Institutional Ownership
AVDL Latest News
-- LUMRYZ is the only FDA-approved once-at-bedtime oxybate treatment for cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy—
– Survey data demonstrate 94% of people with narcolepsy prefer the once-nightly regimen of LUMRYZ over twice-nightly oxybate regimens –
DUBLIN, Ireland, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in the following upcoming investor conferences:
The mean of analysts' price targets for Avadel (AVDL) points to a 43.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
DUBLIN, June 27, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it is set to join the broad-market Russell 3000® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, 2024, according to a preliminary list of additions posted Friday, May 24, 2024.
– 11 accepted abstracts, including new data reiterating satisfaction, preference and clinical benefit of LUMRYZ –
The average price target set by analysts on Wall Street suggests a potential 28.6% increase in Avadel (AVDL). Although the reliability of this metric is uncertain, the positive trend in earnings estimates revisions could lead to a rise in the stock.
Avadel Pharmaceuticals reports strong Q4 2023 earnings for Lumryz, its once-nightly formulation of sodium oxybate for narcolepsy. Lumryz fills a significant gap in narcolepsy treatment by offering a more patient-friendly dosing schedule and improving compliance and patient outcomes. Legal developments, including a favorable jury ruling on patent litigation, reduce legal overhang and instill investor confidence in Avadel's ability to navigate challenges.
DUBLIN, Ireland, March 05, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in the following upcoming investor conferences:
Avadel Pharmaceuticals has made good progress with the launch of Lumryz, enrolling 1,900 patients and generating $19 million in Q4 net sales. Legal risks from competitor Jazz Pharmaceuticals remain a concern, with ongoing litigation and the potential for Lumryz to be pulled from the market. Lumryz can capture a significant portion of the narcolepsy market and expand into idiopathic hypersomnia.
What type of business is Avadel Pharmaceuticals?
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.
What sector is Avadel Pharmaceuticals in?
Avadel Pharmaceuticals is in the Healthcare sector
What industry is Avadel Pharmaceuticals in?
Avadel Pharmaceuticals is in the Drug Manufacturers - Specialty & Generic industry
What country is Avadel Pharmaceuticals from?
Avadel Pharmaceuticals is headquartered in Ireland
When did Avadel Pharmaceuticals go public?
Avadel Pharmaceuticals initial public offering (IPO) was on 07 June 1996
What is Avadel Pharmaceuticals website?
https://www.avadel.com
Is Avadel Pharmaceuticals in the S&P 500?
No, Avadel Pharmaceuticals is not included in the S&P 500 index
Is Avadel Pharmaceuticals in the NASDAQ 100?
No, Avadel Pharmaceuticals is not included in the NASDAQ 100 index
Is Avadel Pharmaceuticals in the Dow Jones?
No, Avadel Pharmaceuticals is not included in the Dow Jones index
When was Avadel Pharmaceuticals the previous earnings report?
No data
When does Avadel Pharmaceuticals earnings report?
The next expected earnings date for Avadel Pharmaceuticals is 08 November 2024